Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating income | -$4.32M | -$21.5M | -$71.5M | -$107M | -$105M | -$142M | -$179M |
| Net income | -$4.32M | -$22.1M | -$71.1M | -$105M | -$96.7M | -$129M | -$162M |
| EPS (diluted) | -$1.66 | -$3.42 | -$1.80 | -$2.62 | -$2.14 | -$2.20 | -$1.87 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.08M | -$19.9M | -$50.7M | -$82.1M | -$83.7M | -$104M | -$147M |
| Capital expenditures | — | $56.0K | $1.57M | $363K | — | $159K | — |
| Free cash flow | — | -$19.9M | -$52.3M | -$82.4M | — | -$105M | — |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $68.0K | $339M | $13.8M | $23.7M | $68.5M | $139M | $48.3M |
| Total assets | — | $343M | $296M | $216M | $277M | $451M | $533M |
| Total liabilities | — | $4.58M | $11.4M | $18.1M | $23.1M | $42.0M | $54.9M |
| Shareholders' equity | -$10.6M | $338M | $285M | $198M | $254M | $409M | $479M |
| Retained earnings | — | -$33.1M | -$104M | -$209M | -$306M | -$435M | -$598M |
| Shares (wtd avg diluted) | 2.59M | 7.02M | 39.5M | 40.0M | 45.2M | 58.7M | 87.0M |
Every figure is extracted from Olema Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.